본문 바로가기
bar_progress

Text Size

Close

Pamir Therapeutics Selected for Deep Tech TIPS Fast Track with Parkinson's Disease Diagnostic Technology

Pamir Therapeutics Selected for Deep Tech TIPS Fast Track with Parkinson's Disease Diagnostic Technology [Photo by Pamir Therapeutics]

Kookmin University (President Seungryeol Jeong) announced on the 12th that Pamir Therapeutics (CEO Cheolgi Moon), recommended by Kookmin University Technology Holdings Co., Ltd., the operator of TIPS, has been finally selected for the Ministry of SMEs and Startups' private investment-led technology startup support program 'Deep Tech TIPS' through a fast track.


Deep Tech TIPS is a program that supports research and development (R&D) funding for three years by matching government funds when private investors select and invest in excellent startup companies, as part of the government's 'Super-gap Startup 1000+ Project' to foster promising startups.


Since the R&D support funds of Deep Tech TIPS are three times the level of the existing TIPS, the evaluation criteria such as technology and business feasibility are stringent. However, Pamir Therapeutics passed the first evaluation by being recognized for its excellent technology and was exempted from the second marketability evaluation through the fast track. Pamir Therapeutics is expected to accelerate research and commercialization by receiving 1.5 billion KRW over the next three years for R&D and startup commercialization funds.


Founded in 2019, Pamir Therapeutics is a research-focused company developing microRNA biomarker-based in vitro diagnostic kits for Parkinson's disease and Alzheimer's disease. During the Deep Tech TIPS selection process, the acquisition of blood microRNA biomarkers and the development of related diagnostic technologies for the realization of RT-qPCR-based Parkinson's disease in vitro diagnostic kits were evaluated as clearly differentiated from existing Parkinson's disease diagnostic methods, creative, and highly excellent in technology.


Cheolgi Moon, CEO of Pamir Therapeutics, said, "We are very pleased to be recognized for our capabilities as a deep tech company and selected through the fast track," adding, "We will grow into a global company representing the research and development field of in vitro diagnostic kits for degenerative brain diseases including Parkinson's disease and Alzheimer's disease."


© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Special Coverage


Join us on social!

Top